Paper Details

  1. Home
  2. Paper Details

Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.

Author: McLaughlinV V

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Pulmonary arterial hypertension (PAH) is a serious condition affecting the small arteries in the lungs, leading to thickening and abnormal growths. Without treatment, both idiopathic PAH (IPAH) and PAH caused by other conditions like scleroderma are often progressive and have high death rates. Researchers are working on treatments specifically for PAH to improve survival. The drug bosentan, which blocks certain blood vessel signals, has been shown to improve exercise ability, time to worsening symptoms, blood flow, and quality of life in short-term studies.
Paper Details　
Original Abstract of the Article :
Pulmonary arterial hypertension (PAH) is a devastating disease of the small pulmonary arteries and arterioles, characterized by intimal fibrosis, medial hypertrophy and plexiform lesions. When untreated both the idiopathic form (IPAH, formerly termed primary pulmonary hypertension, PPH) and PAH rela...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2362.2006.01688.x

データ提供：米国国立医学図書館（NLM）

Bosentan for Pulmonary Arterial Hypertension: A Hopeful Development

Pulmonary arterial hypertension (PAH) is a debilitating disease that affects the small pulmonary arteries and arterioles, leading to a progressive decline in lung function. This review article focuses on the use of bosentan, a dual endothelin (ET(A)/ET(B)) antagonist, as a first-line treatment for PAH. The authors highlight the potential of bosentan to improve exercise capacity, time to clinical worsening, haemodynamics, and quality of life in patients with PAH.

Bosentan: A Promising Treatment Option for PAH

The study's findings offer hope for patients with PAH, demonstrating the potential of bosentan to slow disease progression and improve quality of life. This research underscores the ongoing efforts to develop effective therapies for this challenging condition.

Living with PAH: Finding Hope and Support

PAH can be a daunting diagnosis, but it's important to remember that there are treatment options available. Living with PAH requires a collaborative approach with healthcare professionals and a strong support system.

Dr.Camel's Conclusion

This review provides a glimpse into the evolving field of PAH treatment. As a researcher who has traversed the vast desert of medical knowledge, I am encouraged by the development of new therapies like bosentan. Just as a camel adapts to the harsh desert environment, patients with PAH can adapt to their condition with the right support and treatment.

Date :
  1. Date Completed 2007-02-22
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

16919005

DOI: Digital Object Identifier

10.1111/j.1365-2362.2006.01688.x

Related Literature

Article Analysis
・Effective treatment of pulmonary hypertension
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.